NAGE
Niagen Bioscience Inc · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +6.2% ·
share flow +3.6% ·
net new positions +5.9%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 66 | -4 | 22.69M | $72.48M | +5 | −9 |
| Q1 2026 | 72 | -9 | 26.61M | $117.87M | +3 | −12 |
| Q4 2025 | 81 | 0 | 27.14M | $172.59M | +1 | −1 |
| Q3 2025 | 17 | +1 | 16.56M | $154.47M | +2 | −1 |
| Q2 2025 | 13 | -2 | 14.28M | $205.83M | n/a | −2 |
| Q1 2025 | 12 | +1 | 6.49M | $44.82M | +1 | n/a |
| Q4 2024 | 11 | +2 | 5.06M | $26.83M | +2 | n/a |
| Q3 2024 | 8 | +1 | 2.02M | $7.36M | +3 | −2 |
| Q2 2024 | 7 | n/a | 2.06M | $5.62M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 4.02M | +2.5% | $37.52M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 3.98M | +3.1% | $37.11M | 0.0% | ▲ Add | 2 | SEC ↗ ×10 |
| 3 | Arrowstreet Capital ✦ | 1.44M | +28.4% | $13.41M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.30M | 0.0% | $12.09M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (passive) | 1.09M | +7.1% | $10.19M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | JPMorgan Chase ✦ | 788.33K | n/a | $7.36M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 7 | Millennium Management ✦ | 774.24K | +537.0% | $7.22M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 713.00K | +45.6% | $6.65M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 587.00K | +19.4% | $5.48M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 10 | D. E. Shaw & Co. ✦ | 546.18K | -65.9% | $5.10M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 11 | Morgan Stanley ✦ | 528.37K | n/a | $4.93M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 12 | Goldman Sachs Group ✦ | 378.63K | n/a | $3.53M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 13 | Citadel Advisors ✦ | 199.30K | New | $1.86M | 0.0% | New | 1 | SEC ↗ |
| 14 | GAMCO Investors ✦ | 125.45K | -2.6% | $1.17M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 57.13K | +4.3% | $533,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 16 | Fidelity (FMR) ✦ | 18.46K | +4.3% | $172,217 | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 17 | Gotham Asset Management ✦ | 16.66K | New | $155,484 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $1.86M | 0.0% |
| Gotham Asset Management | $155,484 | 0.0% |
Exited
| Marshall Wace | $2.34M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 142 holders, 36.40M shares, $156.67M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.